Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis
- First Online:
- 211 Downloads
Purpose of this study is to analyze outcomes and pre-treatment prognostic factors in high-risk prostate cancer patients with initial PSA ≥20 ng/mL, treated with high-dose external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) in a single institution.
Between March 2003 and December 2011, 155 consecutive high-risk prostate cancer patients (a) presenting with pre-treatment PSA level ≥20 ng/mL, (b) treated with definitive EBRT, and (c) with a minimum follow-up of 24 months were included in this retrospective analysis. Phoenix definition was used to define biochemical control. Primary endpoints were as follows: biochemical disease-free survival (bDFS), distant metastasis-free survival (DMFS), cancer-specific survival (CSS) and overall survival (OS). Multivariate analysis was performed to determine the independent prognostic impact of pre-treatment clinical factors [T stage, PSA, and Gleason score (GS)].
At a median follow-up time of 62 months, actuarial bDFS, DMFS, CSS, and OS at 5 years were 64.8, 85.2, 95.8, and 94.4 %, respectively. On multivariate analysis, only GS was significantly associated with three clinical endpoints (bDFS: HR 1.6; p = 0.022, CSS: HR 4.27, p = 0.044, OS: HR 2.6; p = 0.038). Pre-treatment zenith PSA was associated only with bDFS (HR 1.87; p = 0.027).
Patients with “high” PSA levels (≥20 ng/mL) showed favorable clinical outcomes, supporting the role of local radiotherapy as primary therapy in combination with long-term ADT in patients with high PSA levels at diagnosis. A GS of 8–10 is the strongest predictor of outcome.
KeywordsHigh-risk prostate cancer External beam radiotherapy Prostate-specific antigen Gleason Score
- Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD et al (2008) Ten-year follow-up of radiation therapy oncology group protocol 92–02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26:2497–2504. doi:10.1200/JCO.2007.14.9021 PubMedCrossRefGoogle Scholar
- Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JD, Haslag-Minoff J et al (2012) Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 187:1259–1265. doi:10.1016/j.juro.2011.11.084 PubMedCrossRefGoogle Scholar
- Ladjevardi S, Berglund A, Varenhorst E, Bratt O, Widmark A, Sandblom G (2012) Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11380 men with serum PSA level 20–100 ng/mL. BJU Int. doi: 10.1111/j.1464-410X.2012.11320.x. (Epub ahead of print)
- Lawton CA, DeSilvio M, Roach M 3rd, Uhl V, Kirsch R, Seider M et al (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94–13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646–655PubMedCrossRefGoogle Scholar
- Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974PubMedCrossRefGoogle Scholar
- Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D et al (2011) Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. Int J Radiat Oncol Biol Phys 80:445–452. doi:10.1016/j.ijrobp.2010.02.034 PubMedCrossRefGoogle Scholar
- Tendulkar RD, Reddy CA, Stephans KL, Ciezki JP, Klein EA, Mahadevan A et al (2012) Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy. Int J Radiat Oncol Biol Phys 82:1397–1404. doi:10.1016/j.ijrobp.2011.04.042 PubMedCrossRefGoogle Scholar
- Zapatero A, García-Vicente F, Martín de Vidales C, Cruz Conde A, Ibáñez Y, Fernández I et al (2011) Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? Int J Radiat Oncol Biol Phys 81:1279–1285. doi:10.1016/j.ijrobp.2010.07.1975 PubMedCrossRefGoogle Scholar
- Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A et al (2008) Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70:1124–1129. doi:10.1016/j.ijrobp.2007.11.044 PubMedCrossRefGoogle Scholar
- Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95–09. JCO 28:1106–1111. doi:10.1200/JCO.2009.25.8475 CrossRefGoogle Scholar